LivaNova

LivaNova is a global medical technology company with nearly five decades of experience. It offers advanced technologies and breakthrough treatments in cardiopulmonary solutions and neuromodulation devices for epilepsy and depression, improving lives of patients worldwide.

Vladimir Makatsaria

CEO

11 past transactions

Cadence Neuroscience

Venture Round in 2023
Cadence Neuroscience develops implantable medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company pursues core technology developed at Mayo Clinic that is being evaluated clinically. The device detects brain signals and delivers electrical stimulation to modulate neural circuits, enabling personalized brain stimulation to improve seizure control relative to existing protocols.

ALung

Acquisition in 2022
ALung Technologies, Inc., established in 1997 and based in Pittsburgh, Pennsylvania, specializes in developing and manufacturing medical devices for treating acute respiratory failure. The company's primary product is the Hemolung Respiratory Assist System, a dialysis-like device that removes carbon dioxide and delivers oxygen directly to the blood, allowing patients' lungs to rest and heal while avoiding intubation and facilitating protective ventilation.

Noctrix Health

Series B in 2021
Noctrix Health, Inc. is an early-stage medical device company founded in 2018 and based in Menlo Park, California. The company specializes in developing therapeutic wearable devices aimed at treating chronic neurological and sleep disorders, particularly focusing on conditions such as restless leg syndrome. Noctrix Health's innovative devices leverage neural circuitry to alleviate symptoms, promoting undisturbed sleep and allowing patients to manage their chronic medical conditions more effectively.

ShiraTronics

Series A in 2019
ShiraTronics develops neuromodulation therapies to treat chronic migraine by delivering continuous stimulation to targeted nerves to relieve, interrupt, and prevent migraine episodes. Founded in 2018 and based in Ireland, the company maintains an additional location in Minneapolis, Minnesota, and pursues innovative neuromodulation technology to address unmet neurological needs and improve patient outcomes.

Ceribell

Series B in 2018
Ceribell designs and manufactures medical devices for acquiring and interpreting electroencephalography (EEG) data in patients with various neurological conditions. Its flagship product, the Ceribell EEG System, includes a headband that accommodates diverse hair types and head sizes, along with a pocket-sized recorder offering clinical quality EEG and on-device display. The system enables healthcare providers to set up EEG monitoring in just six minutes, with a proprietary Brain Stethoscope function converting brainwaves into sound for easier detection of seizures.

TandemLife

Acquisition in 2018
TandemLife is a medical device company that specializes in developing, manufacturing, and marketing innovative products for circulatory support. Their flagship product, the TandemHeart System, is an FDA-cleared device designed to provide extracorporeal circulatory support quickly, making it suitable for use by cardiologists in catheterization labs and cardiac surgeons in operating rooms. The system can deliver up to 5.0 liters per minute of circulatory support percutaneously and up to 8.0 liters per minute with direct surgical cannulation. It consists of a pump that circulates oxygenated blood, a set of cannulae for connecting the pump to the patient, and controllers that manage power, lubrication, and system monitoring. TandemLife's devices are aimed at improving outcomes for patients requiring temporary heart support and reducing healthcare costs.

ImThera Medical

Acquisition in 2017
ImThera Medical, Inc. is a medical device company based in San Diego, California, focused on developing innovative solutions for the treatment of obstructive sleep apnea (OSA). Founded in 2004, the company specializes in implantable neurostimulation devices, notably the aura6000, which is part of its THN Sleep Therapy system. This system employs hypoglossal neurostimulation technology to deliver mild stimulation to key tongue muscles during sleep, thereby maintaining upper airway patency and significantly reducing OSA events. With an estimated 28 million Americans affected by OSA, ImThera aims to provide a viable alternative to traditional therapies, such as CPAP, which often face compliance challenges. By addressing the underlying mechanisms of OSA, ImThera Medical seeks to enhance patient quality of life and alleviate the associated healthcare costs.

HighLife

Series A in 2017
HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating mitral valve regurgitation. Founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve designed to be implanted on a beating heart, allowing for the preservation of the native valve structure and surrounding anatomy. HighLife's innovative system facilitates a transseptal delivery through the femoral vein, enabling a reversible approach that minimizes trauma to patients during surgical procedures. The technology is currently undergoing clinical evaluation, with a focus on ensuring ease and safety of use for healthcare providers.

Caisson Interventional

Acquisition in 2017
Caisson Interventional, LLC, established in 2012 and headquartered in Maple Grove, Minnesota, operates as a subsidiary of LivaNova PLC since May 2017. The company is a clinical-stage medical device manufacturer specializing in the design, development, and evaluation of a novel percutaneous mitral valve replacement system. This innovative system is intended for delivery across the heart's septum via the femoral vein, offering the flexibility to be repositioned or withdrawn before final deployment.

MD Start

Venture Round in 2016
MD Start SA is a medical technology incubator based in Lausanne, Switzerland, that specializes in transforming innovative ideas into viable medical solutions. Founded in 2009, the company creates, develops, and operates medical projects, effectively turning them into new companies. MD Start employs both strategic and hands-on approaches to guide these projects through the investment stage and into commercial development. The firm collaborates with notable partners in the medical device sector, including Medtronic, Sofinnova Partners, and Versant Ventures, among others. Through its focused efforts, MD Start aims to support the growth of medical device start-ups and facilitate the advancement of healthcare technologies.

Cyberonics

Acquisition in 2015
Cyberonics is a company dedicated to developing and marketing medical device solutions for individuals suffering from epilepsy, depression, and other chronic disorders. Their focus is on improving the lives of patients and their families through innovative and patient-focused technology. With a commitment to advancing device-based solutions, Cyberonics aims to provide effective and accessible treatment options for those in need.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.